20 years of revenue, earnings, cash-flow and balance-sheet history from public filings.
First Tracks Biotherapeutics (TRAX) operates in the BIOTECHNOLOGY industry and is headquartered in San Diego, United States with about 104 employees. Its market capitalization is roughly $1 billion.
First Tracks Biotherapeutics, Inc. operates a clinical-stage biotechnology company focused on delivering immunology therapeutics for autoimmune and inflammatory diseases in United States.
Interactive charts & full statements →
| Income statement | TTM → 2026-06-30 | 2025-12-31 | 2024-12-31 | 2023-12-31 |
|---|---|---|---|---|
| Total Revenue | $0M | — | $0M | $0M |
| Gross Profit | — | ($140M) | ($152M) | — |
| Gross Margin % | — | — | — | — |
| Operating Income (EBIT) | ($185M) | ($179M) | ($181M) | ($118M) |
| Operating Margin % | — | — | — | — |
| Net Income | ($173M) | ($166M) | ($164M) | ($106M) |
| Net Margin % | — | — | — | — |
| EBITDA | — | ($178M) | ($179M) | ($116M) |
| Earnings Per Share (EPS) | — | $-4.78 | $-4.71 | $-3.05 |
| Shares Outstanding (M) | 35M | 35M | 35M | 35M |
USD; $M / $B as marked. Newest period first. Source: public company filings (via Yahoo Finance aggregation).
| Quarterly income statement | 2026-06-30 | 2026-03-31 | 2025-06-30 | 2025-03-31 |
|---|---|---|---|---|
| Total Revenue | $0M | $0M | $0M | $0M |
| Gross Profit | $0M | — | — | — |
| Gross Margin % | — | — | — | — |
| Operating Income (EBIT) | ($35M) | ($53M) | ($46M) | ($51M) |
| Operating Margin % | — | — | — | — |
| Net Income | ($33M) | ($50M) | ($42M) | ($47M) |
| Net Margin % | — | — | — | — |
| EBITDA | ($35M) | ($53M) | — | ($51M) |
| Earnings Per Share (EPS) | $-0.94 | $-1.45 | — | $-1.36 |
| Shares Outstanding (M) | 35M | 35M | — | 35M |
USD; $M / $B as marked. Newest period first. Source: public company filings (via Yahoo Finance aggregation).
| Cash flow | TTM → 2026-06-30 | 2025-12-31 | 2024-12-31 | 2023-12-31 |
|---|---|---|---|---|
| Cash from Operations (CFO) | ($148M) | ($143M) | ($126M) | ($93M) |
| Capital Expenditures (CapEx) | $0M | $0M | $0M | $1M |
| Free Cash Flow (FCF) | ($148M) | ($143M) | ($126M) | ($94M) |
| FCF Margin % | — | — | — | — |
USD; $M / $B as marked. Newest period first. Source: public company filings (via Yahoo Finance aggregation).
| Quarterly cash flow | 2026-06-30 | 2026-03-31 | 2025-06-30 | 2025-03-31 |
|---|---|---|---|---|
| Cash from Operations (CFO) | ($32M) | ($33M) | ($39M) | ($45M) |
| Capital Expenditures (CapEx) | $0M | $0M | $0M | $0M |
| Free Cash Flow (FCF) | ($32M) | ($33M) | ($39M) | ($45M) |
| FCF Margin % | — | — | — | — |
USD; $M / $B as marked. Newest period first. Source: public company filings (via Yahoo Finance aggregation).
| Balance sheet | 2026-06-30 | 2025-12-31 | 2024-12-31 | 2023-12-31 |
|---|---|---|---|---|
| Total Assets | $183M | $331M | $442M | $444M |
| Cash & Cash Equivalents | $168M | $238M | $123M | $36M |
| Total Liabilities | $14M | $43M | $50M | $34M |
| Total Debt (Short + Long-Term) | $2M | $2M | $2M | $2M |
| Total Shareholders' Equity | $169M | $287M | $392M | $410M |
USD; $M / $B as marked. Newest period first. Source: public company filings (via Yahoo Finance aggregation).
Quarterly statements, profitability ratios, price history, insider activity and institutional holders are in the interactive TRAX viewer.
About TickerBase · Data methodology & sources · Privacy · Terms